W
William Merhi
Researcher at Spectrum Health
Publications - 30
Citations - 7978
William Merhi is an academic researcher from Spectrum Health. The author has contributed to research in topics: Valve replacement & Stenosis. The author has an hindex of 10, co-authored 19 publications receiving 6117 citations.
Papers
More filters
Journal ArticleDOI
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis
David H. Adams,Jeffrey J. Popma,Michael J. Reardon,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Maurice Buchbinder,James B. Hermiller,Neal S. Kleiman,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Brijeshwar Maini,Mubashir Mumtaz,Sharla Chenoweth,Jae K. Oh +23 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aorti-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aorticsvalve replacement.
Journal ArticleDOI
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
Jeffrey J. Popma,G. Michael Deeb,Steven J. Yakubov,Mubashir Mumtaz,Hemal Gada,Daniel O'Hair,Tanvir Bajwa,John Heiser,William Merhi,Neal S. Kleiman,Judah Askew,Paul Sorajja,Joshua Rovin,Stanley Chetcuti,David H. Adams,P.S. Teirstein,George L. Zorn,John K. Forrest,Didier Tchetche,Jon R. Resar,Antony Walton,Nicolo Piazza,Basel Ramlawi,Newell Robinson,George Petrossian,Thomas G. Gleason,Jae K. Oh,Michael J. Boulware,Hongyan Qiao,Andrew S. Mugglin,Michael J. Reardon +30 more
TL;DR: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self‐expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months.
Journal ArticleDOI
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Michael J. Reardon,N. M. Van Mieghem,Jeffrey J. Popma,Neal S. Kleiman,Lars Søndergaard,Mubashir Mumtaz,David H. Adams,G. M. Deeb,Brijeshwar Maini,Hemal Gada,Stanley Chetcuti,Thomas G. Gleason,John Heiser,Ruediger Lange,William Merhi,Jae Oh,Peter Skov Olsen,Nicolo Piazza,M. Williams,Stephan Windecker,Steven J. Yakubov,Eberhard Grube,Raj Makkar,Jonathan S. Lee,John V. Conte,E. Vang,Hang Nguyen,Yanping Chang,Andrew S. Mugglin,Patrick W. Serruys,Arie-Pieter Kappetein +30 more
TL;DR: TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure.
Journal ArticleDOI
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
Michael J. Reardon,David H. Adams,Neal S. Kleiman,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,Jeffrey J. Popma +26 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, the higher rate of survival with a self-expanding TAVR compared with surgery was sustained at 2 years.
Journal ArticleDOI
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement
G. Michael Deeb,Michael J. Reardon,Stan Chetcuti,Himanshu J. Patel,P. Michael Grossman,Steven J. Yakubov,Neal S. Kleiman,Joseph S. Coselli,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,David H. Adams,Jeffrey J. Popma,CoreValve U.S. Pivotal High Risk Trial Clinical Investigators +29 more
TL;DR: Patients with severe aortic stenosis at increased risk for surgery had improved 3-year clinical outcomes after TAVR compared with surgery, and aorti valve hemodynamics were more favorable in TAVr patients without differences in structural valve deterioration.